Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis

Cong-Qiu Chu, Marco Londei

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Nasal tolerance has recently been used to modulate immune responses in animal models of autoimmunity. We have compared immunogenic collagen type II (CII) peptides for induction of nasal tolerance in DBA/1 mice to collagen- induced arthritis (CIA). Three synthetic peptides corresponding to T cell- stimulating sequences of α1(II)-CB11, 260-270, 245-270 and 259-273, one peptide analog 245-270 (A260B261N263) and one myelin basic protein (MBP) peptide 89-101 were administered intranasally to DBA/1 mice respectively (total 300 μg peptide/mouse on three consecutive days) 10 days prior to CII immunization. Forty percent of CII245-270 (P260-270 (P>0.05) treated mice did not develop arthritis whilst all of the mice treated with CII245-270 (A260B261N263) or CII259-273 developed arthritis compared to those in control groups (PBS- and MBP89-101-treated). The mice in either the CII245-270or CII260-270-treated group which developed arthritis had a significantly delayed onset and their disease was less severe both clinically and histologically. All mice in both CII245-270- and CII260-270- treated groups had a reduced serum level of anti-CII antibody (P

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalJournal of Autoimmunity
Volume12
Issue number1
DOIs
StatePublished - Feb 1999
Externally publishedYes

Fingerprint

Experimental Arthritis
Collagen Type II
Nose
Peptides
Arthritis
Inbred DBA Mouse
Autoimmunity
Immunization
Animal Models
T-Lymphocytes
Control Groups
Antibodies
Serum

Keywords

  • Collagen type II peptides
  • Collagen-induced arthritis
  • Nasal tolerance

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. / Chu, Cong-Qiu; Londei, Marco.

In: Journal of Autoimmunity, Vol. 12, No. 1, 02.1999, p. 35-42.

Research output: Contribution to journalArticle

@article{d65494e9c3b6409fad60e6b4243155a8,
title = "Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis",
abstract = "Nasal tolerance has recently been used to modulate immune responses in animal models of autoimmunity. We have compared immunogenic collagen type II (CII) peptides for induction of nasal tolerance in DBA/1 mice to collagen- induced arthritis (CIA). Three synthetic peptides corresponding to T cell- stimulating sequences of α1(II)-CB11, 260-270, 245-270 and 259-273, one peptide analog 245-270 (A260B261N263) and one myelin basic protein (MBP) peptide 89-101 were administered intranasally to DBA/1 mice respectively (total 300 μg peptide/mouse on three consecutive days) 10 days prior to CII immunization. Forty percent of CII245-270 (P260-270 (P>0.05) treated mice did not develop arthritis whilst all of the mice treated with CII245-270 (A260B261N263) or CII259-273 developed arthritis compared to those in control groups (PBS- and MBP89-101-treated). The mice in either the CII245-270or CII260-270-treated group which developed arthritis had a significantly delayed onset and their disease was less severe both clinically and histologically. All mice in both CII245-270- and CII260-270- treated groups had a reduced serum level of anti-CII antibody (P",
keywords = "Collagen type II peptides, Collagen-induced arthritis, Nasal tolerance",
author = "Cong-Qiu Chu and Marco Londei",
year = "1999",
month = "2",
doi = "10.1006/jaut.1998.0255",
language = "English (US)",
volume = "12",
pages = "35--42",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis

AU - Chu, Cong-Qiu

AU - Londei, Marco

PY - 1999/2

Y1 - 1999/2

N2 - Nasal tolerance has recently been used to modulate immune responses in animal models of autoimmunity. We have compared immunogenic collagen type II (CII) peptides for induction of nasal tolerance in DBA/1 mice to collagen- induced arthritis (CIA). Three synthetic peptides corresponding to T cell- stimulating sequences of α1(II)-CB11, 260-270, 245-270 and 259-273, one peptide analog 245-270 (A260B261N263) and one myelin basic protein (MBP) peptide 89-101 were administered intranasally to DBA/1 mice respectively (total 300 μg peptide/mouse on three consecutive days) 10 days prior to CII immunization. Forty percent of CII245-270 (P260-270 (P>0.05) treated mice did not develop arthritis whilst all of the mice treated with CII245-270 (A260B261N263) or CII259-273 developed arthritis compared to those in control groups (PBS- and MBP89-101-treated). The mice in either the CII245-270or CII260-270-treated group which developed arthritis had a significantly delayed onset and their disease was less severe both clinically and histologically. All mice in both CII245-270- and CII260-270- treated groups had a reduced serum level of anti-CII antibody (P

AB - Nasal tolerance has recently been used to modulate immune responses in animal models of autoimmunity. We have compared immunogenic collagen type II (CII) peptides for induction of nasal tolerance in DBA/1 mice to collagen- induced arthritis (CIA). Three synthetic peptides corresponding to T cell- stimulating sequences of α1(II)-CB11, 260-270, 245-270 and 259-273, one peptide analog 245-270 (A260B261N263) and one myelin basic protein (MBP) peptide 89-101 were administered intranasally to DBA/1 mice respectively (total 300 μg peptide/mouse on three consecutive days) 10 days prior to CII immunization. Forty percent of CII245-270 (P260-270 (P>0.05) treated mice did not develop arthritis whilst all of the mice treated with CII245-270 (A260B261N263) or CII259-273 developed arthritis compared to those in control groups (PBS- and MBP89-101-treated). The mice in either the CII245-270or CII260-270-treated group which developed arthritis had a significantly delayed onset and their disease was less severe both clinically and histologically. All mice in both CII245-270- and CII260-270- treated groups had a reduced serum level of anti-CII antibody (P

KW - Collagen type II peptides

KW - Collagen-induced arthritis

KW - Nasal tolerance

UR - http://www.scopus.com/inward/record.url?scp=0033080994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033080994&partnerID=8YFLogxK

U2 - 10.1006/jaut.1998.0255

DO - 10.1006/jaut.1998.0255

M3 - Article

C2 - 10028020

AN - SCOPUS:0033080994

VL - 12

SP - 35

EP - 42

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

IS - 1

ER -